Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CASP2 | P42575 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11445239 | 0.97 | PRMT1 (0.48) | PRMT1ADRA1AMAPK1KDM4EHIF1A | |
| Hydrochloric Acid SCHEMBL29935745 | 0.97 | PRMT1 (0.43) | PRMT1ADRA1AMAPK1KDM4EHIF1A | |
| SCHEMBL5307349 | 0.92 | KDM4E (0.37) | PRMT1ADRA1AMAPK1KDM4EHIF1A | |
| SCHEMBL1837224 | 0.89 | KDM4E (0.48) | PRMT1MAPK1KDM4EHIF1AALDH1A1 | |
| Palmitamide SCHEMBL9561924 | 0.87 | EPHX1 (0.57) | KDM4EMEN1KMT2ACASP2EPHX1 | |
| SCHEMBL1837168 | 0.86 | KDM4E (0.52) | PRMT1ADRA1AMAPK1KDM4EHIF1A | |
| SCHEMBL28622543 | 0.86 | KDM4E (0.52) | PRMT1ADRA1AMAPK1KDM4EHIF1A | |
| SCHEMBL1839119 | 0.86 | KDM4E (0.52) | PRMT1ADRA1AMAPK1KDM4EHIF1A | |
| SCHEMBL1309360 | 0.86 | KDM4E (0.52) | PRMT1ADRA1AMAPK1KDM4EHIF1A | |
| SCHEMBL28560371 | 0.86 | KDM4E (0.52) | PRMT1ADRA1AMAPK1KDM4EHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120019075-A | Antibody drug conjugates targeting C-MET and methods of use | 酵活英属哥伦比亚有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-119997983-A | Antibody drug conjugate, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| EP-4548937-A1 | ANTIBODY-DRUG COMPLEX | Eisai R&D Management Co., Ltd. (JP) | 2025-05-07 | — | — | EP | disclosed |
| CN-119896745-A | Glycoside-containing peptide linkers for antibody-drug conjugates | R.P.谢勒技术有限责任公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-114025795-B | Methods of treating biliary tract cancer using bispecific antigen binding constructs that target HER2 | 酵活英属哥伦比亚有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-119896746-A | Glycoside-containing peptide linkers for antibody-drug conjugates | R.P.谢勒技术有限责任公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-119306732-B | Bioactive substance conjugate, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119744179-A | Conjugates for targeted therapy | 梁碧惠 | 2025-04-01 | — | — | CN | disclosed |
| CN-119613487-A | Antibody drug conjugates with linkers comprising hydrophilic groups | 诺华股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119613486-A | Antibody drug conjugates with linkers comprising hydrophilic groups | 诺华股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20210355208-A1 | MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF | CYTOMX THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | US | disclosed |
| CN-113651831-A | Bioactive substance conjugate and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-113603703-A | Bioactive substance conjugate and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-11-05 | — | — | CN | disclosed |
| CN-111295389-B | Bioactive substance conjugate and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| EP-3691692-B1 | ANTI-CD71 ACTIVATABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2020-12-30 | — | — | EP | disclosed |
| CN-111295389-A | Bioactive substance conjugate and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2020-06-16 | — | — | CN | disclosed |
| US-10556966-B2 | Anti-HER2 antibodies and immunoconjugates | GENENTECH, INC. | 2020-02-11 | — | — | US | disclosed |
| US-20190177429-A1 | Anti-HER2 Antibodies and Immunoconjugates | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-20180015179-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| WO-2017207540-A1 | ANTIBODY-DRUG-CONJUGATES COMPRISING NOVEL ANTHRACYCLINE-DERIVATIVES FOR CANCER TREATMENT | TOXINVENT OÜ (EE) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355208-A1 | MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF | ADAM8, MMEL1, ADAM33 | PRMT1 916/4885ADRA1A 4667/4885MAPK1 2035/4885 |
| US-20190177429-A1 | Anti-HER2 Antibodies and Immunoconjugates | ERBB2, EGFR, ERBB3 | PRMT1 3812/4885ADRA1A 2699/4885MAPK1 3149/4885 |
| US-10556966-B2 | Anti-HER2 antibodies and immunoconjugates | ERBB2, EGFR, ERBB3 | PRMT1 3812/4885ADRA1A 2699/4885MAPK1 3149/4885 |
| US-20180015179-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES | CD79B, CD99, CD47 | PRMT1 1355/4885ADRA1A 3093/4885MAPK1 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.